Evotec SE (EVOTF) Shares Outstanding (Weighted Average) (2019 - 2026)
Evotec SE's (EVOTF) quarterly Shares Outstanding (Weighted Average) came in at $208.2 million in Q1 2026, up 11.37% year-on-year from $187.0 million in Q1 2025, and up 0.63% quarter-over-quarter from $206.9 million in Q4 2025.
Evotec SE (EVOTF) Shares Outstanding (Weighted Average) (2019 - 2026) Analysis & Trends
Evotec SE has disclosed Shares Outstanding (Weighted Average) across 8 years of filings, most recently posting $208.2 million for Q1 2026.
- Shares Outstanding (Weighted Average) for Q1 2026 came in at $208.2 million, up 11.37% year-over-year; the trailing twelve-month figure through Mar 2026 was $208.2 million (up 11.37% YoY), and the FY2025 annual result was $206.9 million, up 9.07% from the prior year.
- Shares Outstanding (Weighted Average) came in at $208.2 million for Q1 2026 at Evotec SE, up from $206.9 million in the prior quarter.
- In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $208.2 million in Q1 2026 to a low of $178.2 million in Q3 2022.
- The 5-year median for Shares Outstanding (Weighted Average) is $192.6 million (2023), against an average of $194.1 million.
- Peak annual rise in Shares Outstanding (Weighted Average) reached 10071788.09% in 2022, while the deepest fall reached 5.31% in 2022.
- Evotec SE's Shares Outstanding (Weighted Average) stood at $180.3 million in 2022, then grew by 5.6% to $190.4 million in 2023, then slipped by 0.33% to $189.7 million in 2024, then advanced by 9.07% to $206.9 million in 2025, then grew by 0.63% to $208.2 million in 2026.
- The last three Shares Outstanding (Weighted Average) figures came in at $208.2 million (Q1 2026), $206.9 million (Q4 2025), and $207.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Weighted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 1.16 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 422.10 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 43.50 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 5.02 Bn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 100.50 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 497.70 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 166.20 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 228.36 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 64.74 Mn |
| 10 | Evotec SE | - | - | - | 208.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 208.25 Mn |
| Dec 31, 2025 | 206.94 Mn |
| Sep 30, 2025 | 207.71 Mn |
| Jun 30, 2025 | 201.23 Mn |
| Mar 31, 2025 | 186.99 Mn |
| Dec 31, 2024 | 189.73 Mn |
| Sep 30, 2024 | 194.77 Mn |
| Dec 31, 2023 | 190.35 Mn |
| Sep 30, 2023 | 192.61 Mn |
| Jun 30, 2023 | 192.67 Mn |
| Dec 31, 2022 | 180.25 Mn |
| Sep 30, 2022 | 178.16 Mn |
| Jun 30, 2022 | 188.55 Mn |
| Mar 31, 2022 | 198.60 Mn |
| Dec 31, 2021 | 190.36 Mn |
| Sep 30, 2021 | 1,768.93 |
| Jun 30, 2021 | 83,094.73 |
| Mar 31, 2021 | 197.93 Mn |
| Dec 31, 2020 | 183.32 Mn |
| Sep 30, 2020 | 46.72 |